Biotechnology

How Does DNA Sequencing Work?

DNA sequencing determines the order of the four chemical bases, A, C, G, and T, in a DNA molecule. Most methods work by copying DNA and detecting each base as it is added. Here is how the main approaches compare.

Key points

  • DNA sequencing reads the order of the four bases (adenine, thymine, cytosine, and guanine) along a DNA molecule.
  • Most methods rely on base pairing: A pairs with T and C pairs with G, so copying a strand reveals its sequence.
  • Sanger sequencing, published in 1977, reads one fragment at a time with high accuracy and is still used to confirm results.
  • Next-generation sequencing reads millions of short fragments in parallel. Long-read methods read much longer single molecules.
  • Sequencing is only the first step: software must assemble the reads and interpret the differences found.

Every genetic test, genome study, and gene-targeted drug depends on one basic capability: reading DNA. DNA sequencing is the process of determining the exact order of the chemical letters in a DNA molecule. This guide explains the principle that nearly all methods share and how the main technologies differ.

What is being read

DNA is built from four chemical bases: adenine (A), thymine (T), cytosine (C), and guanine (G). Their order along the molecule encodes genetic information. NHGRI explains that sequencing data can show which stretches of DNA contain genes, which carry regulatory instructions, and where changes may cause disease.

DNA has two strands that wind around each other in the double helix described by James Watson and Francis Crick in 1953. The bases on the two strands pair in a fixed way:

  • A always pairs with T
  • C always pairs with G

This pairing is how cells copy DNA, and NHGRI notes that it also underlies the methods by which most sequencing is done. If you know one strand, you know the other.

The shared principle: read DNA by copying it

Most sequencing methods follow the same logic:

  1. Separate the two DNA strands.
  2. Copy one strand using an enzyme called DNA polymerase, which adds bases one by one according to the pairing rules.
  3. Detect which base is added at each position.
  4. Record the sequence of detected bases.

The technologies differ mainly in how they detect each base and how many DNA molecules they read at once.

Sanger sequencing

Published by Frederick Sanger and colleagues in 1977, Sanger sequencing uses modified bases that stop the copying process wherever they are added. The result is a collection of DNA fragments of every possible length, each ending at a known base. In modern versions, each terminating base carries a different fluorescent color, and the fragments are sorted by size. Reading the colors in order of fragment length gives the sequence.

Strengths Limitations
Very high accuracy Reads one DNA fragment per reaction
Reads of several hundred bases Slow and expensive for whole genomes
Still used to confirm important variants Not suited to detecting rare variants in mixed samples

The Human Genome Project, which ran from 1990 to 2003, relied largely on Sanger-based sequencing.

Next-generation (short-read) sequencing

Next-generation sequencing (NGS) reads millions of short DNA fragments at the same time. In the most common approach, fragments are attached to a surface, copied into clusters, and then extended one base at a time with fluorescently labeled bases. A camera records which color lights up at each cluster after every step.

Because it reads so many fragments in parallel, NGS made sequencing whole genomes routine. Each read is short, typically a few hundred bases, so software must piece them together. See What Is Next-Generation Sequencing?

Long-read sequencing

Long-read technologies read individual DNA molecules thousands to hundreds of thousands of bases long. Two main approaches are in use:

  • Watching a single DNA polymerase copy a molecule in real time, detecting each fluorescent base as it is added.
  • Threading a DNA strand through a tiny pore and measuring changes in electrical current as each base passes through.

Long reads can span repetitive regions and large rearrangements that short reads cannot resolve. They were essential to the first complete, gap-free human genome sequence, published in 2022.

Comparing the approaches

Sanger Short-read NGS Long-read
Molecules read at once One per reaction Millions Thousands to millions
Typical read length Several hundred bases A few hundred bases Thousands of bases or more
Best for Confirming specific variants Whole genomes, exomes, panels, RNA Repetitive regions, structural variants, complete assemblies

After the reads: assembly and analysis

Raw reads are not a genome. They must be:

  1. Checked for quality,
  2. Aligned to a reference genome, or assembled from scratch,
  3. Compared with the reference to find variants, and
  4. Interpreted to decide which variants matter.

This computational work is the domain of bioinformatics, and it is often slower and harder than the sequencing itself.

Why sequencing matters for drug development

  • Finding targets: sequencing large populations links genes to disease.
  • Selecting patients: sequencing tumors identifies mutations that match targeted drugs.
  • Diagnosing rare diseases: sequencing can reveal the genetic cause and identify patients for gene-targeted trials.
  • Monitoring treatment: sequencing tumor DNA in blood can show how a cancer is responding.

Sources

  1. National Human Genome Research Institute. DNA Sequencing Fact Sheet.Regulator
  2. Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature. 1953;171:737–738.Peer-reviewed
  3. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proceedings of the National Academy of Sciences USA. 1977;74(12):5463–5467.Peer-reviewed
  4. Nurk S, et al. The complete sequence of a human genome. Science. 2022;376(6588):44–53.Peer-reviewed
  5. National Human Genome Research Institute. The Human Genome Project.Regulator

This article is for education. It is not medical advice and not investment advice. Figures are drawn from the sources above and describe historical averages, not the prospects of any particular drug. See our editorial standards and disclaimer.